Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 159

1.

CKD-induced wingless/integration1 inhibitors and phosphorus cause the CKD-mineral and bone disorder.

Fang Y, Ginsberg C, Seifert M, Agapova O, Sugatani T, Register TC, Freedman BI, Monier-Faugere MC, Malluche H, Hruska KA.

J Am Soc Nephrol. 2014 Aug;25(8):1760-73. doi: 10.1681/ASN.2013080818. Epub 2014 Feb 27.

2.

Early chronic kidney disease-mineral bone disorder stimulates vascular calcification.

Fang Y, Ginsberg C, Sugatani T, Monier-Faugere MC, Malluche H, Hruska KA.

Kidney Int. 2014 Jan;85(1):142-50. doi: 10.1038/ki.2013.271. Epub 2013 Jul 24.

3.

Effects of phosphate binder therapy on vascular stiffness in early-stage chronic kidney disease.

Seifert ME, de las Fuentes L, Rothstein M, Dietzen DJ, Bierhals AJ, Cheng SC, Ross W, Windus D, Dávila-Román VG, Hruska KA.

Am J Nephrol. 2013;38(2):158-67. doi: 10.1159/000353569. Epub 2013 Aug 7.

4.

Phosphate handling in CKD-MBD from stage 3 to dialysis and the three strengths of lanthanum carbonate.

Cozzolino M, Bruschetta E, Cusi D, Montanari E, Giovenzana ME, Galassi A.

Expert Opin Pharmacother. 2012 Nov;13(16):2337-53. doi: 10.1517/14656566.2012.730520. Epub 2012 Oct 4. Review.

PMID:
23033914
5.

Klotho/FGF23 Axis in CKD.

Tsuchiya K, Nagano N, Nitta K.

Contrib Nephrol. 2015;185:56-65. doi: 10.1159/000380970. Epub 2015 May 19. Review.

PMID:
26023015
6.

Osteo-renal regulation of systemic phosphate metabolism.

Razzaque MS.

IUBMB Life. 2011 Apr;63(4):240-7. doi: 10.1002/iub.437. Epub 2011 Mar 24. Review.

7.

The chronic kidney disease - Mineral bone disorder (CKD-MBD): Advances in pathophysiology.

Hruska KA, Sugatani T, Agapova O, Fang Y.

Bone. 2017 Jul;100:80-86. doi: 10.1016/j.bone.2017.01.023. Epub 2017 Jan 22. Review.

PMID:
28119179
8.

[New Developments in CKD-MBD. Why is phosphate overload harmful?].

Kuroo M.

Clin Calcium. 2014 Dec;24(12):1785-92. doi: CliCa141217851792. Japanese.

PMID:
25423923
9.

From skeletal to cardiovascular disease in 12 steps-the evolution of sclerostin as a major player in CKD-MBD.

Brandenburg VM, D'Haese P, Deck A, Mekahli D, Meijers B, Neven E, Evenepoel P.

Pediatr Nephrol. 2016 Feb;31(2):195-206. doi: 10.1007/s00467-015-3069-7. Epub 2015 Mar 4. Review.

PMID:
25735207
10.

Disturbances of Wnt/β-catenin pathway and energy metabolism in early CKD: effect of phosphate binders.

de Oliveira RB, Graciolli FG, dos Reis LM, Cancela AL, Cuppari L, Canziani ME, Carvalho AB, Jorgetti V, Moysés RM.

Nephrol Dial Transplant. 2013 Oct;28(10):2510-7. doi: 10.1093/ndt/gft234. Epub 2013 Aug 23.

PMID:
23975746
11.

Pathophysiology of the chronic kidney disease-mineral bone disorder.

Hruska KA, Seifert M, Sugatani T.

Curr Opin Nephrol Hypertens. 2015 Jul;24(4):303-9. doi: 10.1097/MNH.0000000000000132. Review.

12.

[Vascular Calcification - Pathological Mechanism and Clinical Application - . Vascular calcification in chronic kidney disease-mineral and bone disorder (CKD-MBD)].

Omata M, Fukagawa M, Kakuta T.

Clin Calcium. 2015 May;25(5):645-53. doi: CliCa1505645653. Review. Japanese.

PMID:
25926567
13.

Circulating sclerostin and Dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness.

Thambiah S, Roplekar R, Manghat P, Fogelman I, Fraser WD, Goldsmith D, Hampson G.

Calcif Tissue Int. 2012 Jun;90(6):473-80. doi: 10.1007/s00223-012-9595-4. Epub 2012 Apr 21.

PMID:
22527202
14.

The role of bone in CKD-mediated mineral and vascular disease.

Khouzam NM, Wesseling-Perry K, Salusky IB.

Pediatr Nephrol. 2015 Sep;30(9):1379-88. doi: 10.1007/s00467-014-2919-z. Epub 2014 Aug 29. Review.

PMID:
25168424
15.

[New Developments in CKD-MBD. Development and progression of CKD-MBD in predialysis period -when and how?].

Komaba H.

Clin Calcium. 2014 Dec;24(12):1771-8. doi: CliCa141217711778. Review. Japanese.

PMID:
25423921
16.

Women and CKD-mineral and bone disorder.

Ho LT, Sprague SM.

Adv Chronic Kidney Dis. 2013 Sep;20(5):423-6. doi: 10.1053/j.ackd.2013.06.007. Review.

PMID:
23978548
17.

Is chronic kidney disease-mineral bone disorder (CKD-MBD) really a syndrome?

Cozzolino M, Ureña-Torres P, Vervloet MG, Brandenburg V, Bover J, Goldsmith D, Larsson TE, Massy ZA, Mazzaferro S; CKD-MBD Working Group of ERA-EDTA.

Nephrol Dial Transplant. 2014 Oct;29(10):1815-20. doi: 10.1093/ndt/gft514. Epub 2014 Feb 9.

18.

Effects of unfractionated heparin on renal osteodystrophy and vascular calcification in chronic kidney disease rats.

Meng Y, Zhang H, Li Y, Li Q, Zuo L.

Bone. 2014 Jan;58:168-76. doi: 10.1016/j.bone.2013.10.010. Epub 2013 Oct 18.

PMID:
24145307
19.

Assessment of tubular reabsorption of phosphate as a surrogate marker for phosphate regulation in chronic kidney disease.

Hong YA, Lim JH, Kim MY, Kim Y, Yang KS, Chung BH, Chung S, Choi BS, Yang CW, Kim YS, Chang YS, Park CW.

Clin Exp Nephrol. 2015 Apr;19(2):208-15. doi: 10.1007/s10157-014-0962-5. Epub 2014 Apr 1.

PMID:
24682550
20.

FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality.

Shalhoub V, Shatzen EM, Ward SC, Davis J, Stevens J, Bi V, Renshaw L, Hawkins N, Wang W, Chen C, Tsai MM, Cattley RC, Wronski TJ, Xia X, Li X, Henley C, Eschenberg M, Richards WG.

J Clin Invest. 2012 Jul;122(7):2543-53. doi: 10.1172/JCI61405. Epub 2012 Jun 25.

Supplemental Content

Support Center